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X-‘7hCGRP IS a potent antagomst at calcltonm gene-eclated peptlde (CGRP) lwcr membrane receptors, It also blocks VdSO&!dtOr actlons of CGRP 
and the related peptlde, amyhn, m Intact rats We now report thdt ‘A IlCGRP antagomzes amylm mhlbltlon of msuhn-stimulated labelled glucose 
uptake rnto lsolnted mt solcus muscle, and mhlblts amyhn-evoked elevation of plasma lastatc and glucose m fasted anaesthetlzed rats The different 
rclatlve potencies of the 3 hgands (dmylm CGRP, “-“hCGRP) on the liver receptor dnd on the soleus muscle pomt to dlstmct CGRP receptors 
m liver membranes and dmylm receptors on muscle cells 
Amyhn, Calcltonm gene-related peptlde, Rat soleus muscle, Glucose, Lactate. Plasma calcium 
1 INTRODUCTION 
Amyhn IS a 37-ammo acid protein which IS the major 
constituent of the islet amytold found m type 2 dlabetlc 
patients [I] Amylm 1s expressed prlmarlly m pancrcatlc 
p-cells and IS co-secreted from these cells along with 
msuhn, followmg stlmulatlon by nutnents such as glu- 
cose and a!g!nme [a]. Amylm exerts powerful effects on 
glucose metabolism m isolated skeletal muscle, and m 
intact animals. In isolated rat soleus muscle, amylm was 
found to inhibit msulm-stimulated mcorpolatlon of la- 
belled glucose mto glycogen with an ECso near 1 0 nM 
[S] Among subsequently reported effects of amyhn on 
skeletal muscle m vitro 1s a decrease m glucose uptake 
[4], an increase In lactate production [3]. a decrease m 
total glycogen [5] and activation of phospho! ylase-a, the 
rate hmltmg enzyme fo! glycogen bteakdown [6,7] 
Calcltomn gene-ielated pept!de (CGRP) 1s a widely 
dlstrlbuted perlphclal and central neurotransmltter 
Amylm and CGRP are structurally related, a-hCGRP 
and P-hCGRP have respectively 43 and 46% ammo ac!d 
sequence identity w!th human amylm as shown m F!g 
1 All known forms of amylm and CGRP share 2 post- 
translational mod!ficat!ons essential for full blologlcal 
activity, namely a Cys’-Cys7 dlsulfde bond and an am!- 
dated C-termmal carboxyl group [8] Amylm and 
CGRP also appear to be functionally related They both 
mhlblt msulm-stnnulated mcorporat!on of labelled glu- 
cose into glycogen with compardble potency [3] CGRP 
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IS a potent vasodllator [9], and amylm also has vasod!la- 
tor activity [lo-121 
In VIVO, amyhn IS reported to reduce msulm-stlmula- 
ted glucose clearance, and partly to reverse insulin mhl- 
bltlon of hepatlc glucose output !n ammals during hype- 
rinsulinemic euglycaemic clamps [13-l 51 Infusions of 
CGRP are reported to exe! t slm!lar effects [I 3,1 G]. Both 
amyhn [17,1&] and CGRP [19,20] have a hypocalcemic 
action through the mhlbitlon of bone resorption We 
have found that intravenous injections of amyhn [12] 
and CGRP evoke a slmllar spectrum of responses, but 
with different relative potencies, CGRP IS approxlma- 
tely 65 tlmcs more potent as a hypotenslve agent than 
IS amylm and evokes more prolonged falls m blood 
pressure, CGRP IS slightly less potent than amyhn m 
evoking increments m lactate and glucose, but IS shghtly 
more potent m promotmg decrements m calcium (M - 
W Wang et al, m preparation). 
CGRP and amylm may evoke their phsylologlc re- 
sponses via a family of membrane receptors at which 
they act with different relative potencies The CGRP 
Position 5 10 15 20 25 30 35 
I I I I I I I 
Human amyl In KCNTATCATQRLeANPLVllSSNNFGAILSSTNVGSNTY-KIix 
Rat amylin KCNTATCAlQI&AI$FLVRSSNNLGPVLPFTNVGSNTY-N% 
a-hCGRP ACDTATCVTHRLAGLLSRSGGVVKNN E’VPTNVGSKAP-NH, 
R-hCGRP ACNTATCVTllRLAGLLSRSGGHVKSNFVPTNVGSKAF-t% 
’ “hCGRP VTID&AGLLSRSGGVVKNN FVFTNVGSKAF-KU, 
I_ 
!-lg ! kIllno xld wqucnccs SCqUenWS Of hUmdn dIllyhI, rdt dmy!lIl, 
a-human cdlcltontn gcnc-reldted pcptidc (CGKP), /?-humdn CGRP. 
dlld ’ “hCGR!’ FOr dll CXCCpt the !,lSt, thCrc IS dn lIltrdnlO!CCU!dr 
dwlhdc hnkdgc bctwccn Cys: dlld cys’ 
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FragIllent, ‘-I’ hCGRP, which displaces labelled CGRP 
from liver membranes with an apparent affinity of 260 
pM, has proved to be a competItlve antagonist m III- 
hlbltmg CGRP actlvatlon of adenylate cyclase [21] In 
vlvo 8-37CGRP reversibly mhlblted the vasodtlator ac- 
tlon’of CGRP [22], and has been shown to inhlbrt the 
vasodllator action of amylm [11,12] In the present ex- 
periments, we report the action of “-37hCGRP to block 
amylm responses m Isolated rat soleus muscle. and to 
block the hyperlactaemlc and hyperglycaemlc responses 
to a 25 5 nmol Intravenous bolus of amylm m fasted 
anaesthetlaed rats 
2. MATERIALS AND METHODS 
Z I Mrrrevrols 
2 I I Atrands For m VLVO euperlmcnts. Harlan Sprague-Dawley 
rats (33219 g, males, dge 93+5 days) were used The) were housed at 
22 720 8°C III d 12 12 hour hght dark cycle (experiments bemg per- 
formed during the hght cycle) and fed and watered rd hbttum (Diet 
LM-485. Tekbd, Mddlson. WI) Animals were fasted for 2020 5 h 
before expenments For lsoldted soleus muscle assays, rats weighed 
200-250 g and were fasted for 4 h before use 
2 I 2 C/zetniccr/\ Soluble IIISUIIII, (Humulm-R. 100 U/ml) was par- 
chased from El, L,,iy dnd Co . Indldndpohs, IN The converSion factor 
between activity units, U. and molar units for msuhn used III the 
present study WdS I ,uU/ml=7 I pM Human “-“CGRP (Lot #ZH201) 
WJS from Eachem (Torrdnce, CA) Chenucal Identity and purity of 
tins peptldc wds determmed as being around 98% by ammo acid 
analysis. gds phdbe protem sequencmg, and FAB mass spectrometry 
Smce acttvitles of synthesized dmyhn vdry [23]. the dctrvity of mt 
dmjhn [f4] used m this study (lot #ZG485, Bachem) ~‘1s first determr- 
ned using the soleus muscle-based ssdy [3,2.5], the medsurcd ECSo wds 
6 7? I 5 nM Stock solutions ot rdt dmylm and ‘-“hCGRP were prepa- 
red fresh ddily in I50 mM NdCl Concentrations of dmqlin and ” ” 
hCGRP m protcm-fret stock solutions were verified usmg qunntltdtlve 
ammo .~c:d n,dys~s as previously descllbed [26] 
[U-“Cl-g!ucose (I2 6 GBq’mmol) was purchased from New England 
Nuclear(Wilmmgton. DE) All other redgents were ofdndlytlcdl grade 
or better 
Isolntlon ‘md mcubatlon ol stnpped rdt solcus muscles m the plcs- 
ence ot venous concentrdtlons ot insulin, dmyhn dnd “-“hCGRP. and 
detcrmindt~on of rntcs ot radloglucosc lncorpoiatlon mto glycogen. 
were performed dcbordmg to previously described methods [3.25] 
MLISC~CS weie pre-mcubated m Erlemneyer flasks contammg IO ml 
Krebs- Ringer bicdrbonate buffer nt 37’C with the following composi- 
tion (in mM) NdCI, I18 5. NdHCO,. 25. KCI. 5 94, CdCl,. 2 54. 
KH2P0.,, I !9. MgSOJ, I 19. D-glucose. 5 5. pH 7 40 Flasks were 
g&sed continuously with O2 CO2 (95 5 v/v) Attcl preincubdtlon of 
muscles in this mcdlum for 30 mm dt 37°C III dn oscilldtmgwdter bdlh 
muscle strips weie tldnsferred Lo simlldr vldls Lontauiing the \dnlc 
medium with .~dded [LJ-‘JC]gluco6e (dt 0 5pWml). human msulm (7 I 
nM). rdt nmyhn (100 nM) dnd mcrcnslng conccnltntmns of ’ ” 
hCGRP(0, I IO. 100, 1000. 1x10” 3x10”. 1x10’ nM) (I-lg 3) Mubclcs 
wcrc mcubdtcd ford further GO mm, then bloucd and [U-“‘C]glu~o~c 
uicorpotation into glycogcn wds nicd5urcd Four niusclc \trlpb wcrc 
uwubdtcd dt CA trcatmcnt condltlon. .uid c,~cb cxpcl t~ncn~ w.15 IC- 
pcacd 7 tlnw 
2 3 Ill II\0 rrrcrlrntis 
2 3 I Jutj&!r L trml1IIJI~f~I~I(‘~If~///u)I htacsthcstd WJS mduLcd In 18-h 
fd\tcd I.ltS Ll\lllg 5% hdlOlll.lllL! WhlCh W.I\ ttlCll llldllltkllllCd all 2% 
durmg Turgcry dnd at0 8 I Y0 durmgsubrcqucnt mccdbolic rccordmgs 
Trdchcotomy dnd cdnnuldr~on 01 right fcmordl dt tcry dnd vcm !tcic 
pcrformcd and core tcmpcrdturc cont~ollcd \\ lth ‘1 thcl morcguldtar 
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(Model 73A. YSI, Yellow Springs, OH) which switched a heated 
operatmg tnble 
The femoral arterial line was connected to d pressure transducer 
(Spectramed P23XL transducer, Model 13-4615-58 amphfier, Gould, 
Cleveland, 01-t) and perfused with heparunzed saline (2 U/ml) at 3 0 
ml/h The femoral venous line was used for acute (bolus) Injections. 
nnd ‘-“hCGWP was added to this mfusate for chrome admuustra- 
tion 
Signals For drterlal pressure were sampled and stored with l2-bit 
preclslon at 20 Hz nsmg a computen7ed data acqmsltlon system 
(DT280lA A/D concerters, DntaTranslatlon, Marlboro. MA, AST 
Premium 386 computer, AST Research. Irvme, CA Labtech Note- 
book softwnre, Laboratory Tcchnologles Corp. Wllmmgton. MA) 




Amyhn bolus (n=7) after an lmtlal 2-h mfuston. ammals received 
100 ~1 (I v ) sdhne contammg 25 5 nmol freshly &solved rat 
anlylm. 
X“7hCGRP Prlmed contmuous mfuslon with amyhn bolus (n=3) 
ammdls were Injected at Y=-30 mm with n I60 nmol bolus of 
s-“hCGRP. Followed by d contmuous mfuslon of this peptlde at 
I 6~umol:h for 2 h, then at 320 nmollh lor d Further hour, the total 
’ “hCGRP dehvered bemg 3 7 flmol/rdt (I 1 I pmol/kg) At Y=O 
min. nmmdls received 100 PI (Iv ) sahne contammg 25 5 nntol 
Fresh rat amyhn as in the group dbovc 
Salme conrrols (~1=7), instead of fresh amyhn. rdts were injected 
with IOOfll 01 salme \chlcle 
Arterial samples were drawn 0 5. 0 25 and 0 h before. and 0 5, I, 
I 5, 2. 3, and 4 h dfter bolus mjection Samples were collected mto 
hepdrmizcd capillaries dnd separated plasma analyed for glucose, ldc- 
tote and totdl calcmm Glucose and lactate wcrc dndiyzcd by Immobl- 
hzed enzyme chemlstrlcs (glucose oxldase L-lactate oxiddse. Analyzer 
model 2300-STAT, YSI. Yellow Springs. OH) Cdlcnmr wds measured 
usmg d dye-bmdmg assay (o-Cresolphthdlein complexone. Slgmd pro- 
cedure #5&X7, Slgmd Chcmlcal Co. St LOUIS, MO) 
Stdttstlcdl dndlysls Wds performed using the non-pdlred t\co-t&led 
Student’s r-test (pooled vdrlances method) contamed m the SkSTAT 
system [27]. with levels of signlficdna ds stdtcd Results dre reported 
‘IS means ?SEM Sigmcnd dose-response nnalyses flom which E& 
vnlucs were derived, used d least-squdrcs Iterauve routine to fit d 
J-pdrdmelcr logistic tunctlon [78] 
3 RESULTS AND DISCUSSION 
Flgutc 2 shows that 100 PM “-‘lhCGRP could com- 
pletely abrogate the ability of 100 nM rat amyhn to 
suppress insulin-stnnulated mcorpolatlon of labelled 
glucose into glycogen m isolateki at soleus muscle Thus 
result IS most readily dttrlbu d to blockade of amylm 
dctlon at the cell surface, presumably at amyhn recep- 
tors since both amylm and X-77hCGRP die large molecu- 
les ‘tnd thelcfole unlikely to permeate cell membranes 
The design of the experiment makes it unlikely th‘lt 
’ “hCGRP was acting m some non-specllic manner, 
because it restored a cotnplcx metabohc lesponsc to 
insulin Apphed m the absence of dmylm, 100 PM 
’ “hCGRP did not change msut ln-8tmn&lted gtucolc 
incolpolatlon into gtycogen, llldlcatlllg that 
s “hCGRP tins no amyhn-agonist activity in this assay 
Figure 3 shows the dose-response ctnve for 
x “hCGKP m the solcus mu& preparation. In the 
p~cscncc of 100 nM lat amyhn, the IC,, 15 calculated to 
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I lnsulln 9 1nM I 
Basal Ill%ulln InsuIln lnsulln 
c Amyhn + Amyhn 
-I- Antagonist 
Fig 2 In vitro agomst and antagomst actlvlty Isolated soleus muscles 
were pre-Incubated for 30 mm m Kiebs-Rmgci blcarbondte buffer 
contdmmg no added hormones (basdl), 7 I nM msuhn, 7 I nM msuhn 
+ 100 nM amyhn. and 7 I nM msulm + 100 nR4 amyhn + IOOpM 
‘-“hCGRP Net mcorporatmn of [U-‘4C]glucose ddded to the m&urn 
for the next hour was measured m extracted glycogen and expressed 
ds the calculated late of glucos>l umts trdnsferred onto glycogen/h/g 
wet muscle rr=l2 muscle strips, menns t SEM 
be 5 9 PM with a standard error of ?O 13 log units 
Schlld analysis [29] of the shifts rnvoked by 8-37hCGRP 
(0 1, I, IQ, 30, 100 ,&I) m the amylm dose-response for 
suppression of msulm-stimulated glucose mcorporatlon 
Into soleus muscle glycogcn (data not shown) returned 
a p& of 7 1, correspondmg to a KB of 80 nM That IS, 
Zero 10'0 10" IO" 10’ 104 10” IO4 105 
* 37hCGRP concentration In medium (molar) 
Tlg 1 In vltio dose-rcsponrc In vi110 dowrcspollsc fol the dntd- 
gOn1sm by ’ ’ %CGRP of thccffcct of 100 nM dmyhn to Inhlblt IIMIIIW 
stlmulatcd [U-~‘C]glw3~~c Inrorpoi-dtioil ni glycogcn 111 iwldtcd solcu~ 
lllusclC Ihc c\tlmdtcd FK,, U.I\ 5 92 PM 40 I3 log UIlll~ 
“-371~CGRP has an apparent & for skeletal muscle 
amyhn receptors about 300 times greater than the value 
of 260 pM reported for dlsglacement of CGRP from 
membranes [21] Thus, as previously reported in the 
liver membrane assay, 8-37hCGRP has a higher affinity 
than does amylm while m the soleus muscle assay 
amylm has a higher affinity than does 8-37hCGRP. 
These results further mdlcate that amyhn (and CGRP) 
effects on skeletal muscle are medlatcd via receptors 
distinct from those m liver membranes. Collectively, the 
data m the present study combined with previous 
reports suggest he followmg order of potency for three 
hgands considered here. for the liver receptor, 
CGRP~8-37hCGRP>amylm, and for the soleus muscle 
receptor, amylm?-CGISP~8-37hCGRP 
3.2 Effects m anaesthetced rats 
Figure 4 shows that intravenous mfuslon of 
8-37hCGRP mto anaesthetlzed rats suppressed the m- 
crease m plasma lactate and glucose normally evoked 
by an intravenous bolus of 25 5 nmol rat amylm The 
transient fall m blood pressure normally evoked by this 
dose of amyhn was also blocked, confirming pievlous 
findings [l l] lnhlbltron of the vasodllatlon IS unlikely 
to explain the mhlbltlon of the lactaemlc and glycaemlc 
response to amylm since these responses also occurred 
followmg subcutaneous amylm uqectlon when there 
was no change m blood pressure 8 “hCGR.P itself 
evoked slgmficant changes m neither plasma lactate and 
glucose, nor m blood pressure at blocking doses Inter- 
estingly, infusion of ’ 37hCGRP appeared not to mhlblt 
ctate 
Hours after amylln Injectton 
1-q 4 Iii VIVO dniyhn dgorwt dnd dntdgomst responses Ainylm- 
IndUCCd LhdllgCS In pl.lSmd gtUCOSC (’ ) &Id IdLtdtC (a) WlttlOUt 01=7) 
,tnd with (e. a. 11-3) ,I prllncd-contlnuou4 ” “hCclR1’ lnfuslon I’hc 
lc~pollrc to sdhnc :11011C ( , rr=7) 15 .IIW rhow Symbol5 rcprcrcnt the 
IllCdn’, ” SLM 
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the calcium lowermg effect of rat amylm (data not 
shown). This result 1s consrstent with an amylm m- 
fluence on calcium homeostasrs via actions on 
osteoclasts [17,181 through receptors dlstmct from those 
medlatmg amyhn acttons m skeletal muscle and from 
those medtatmg vasodllator effects 
It IS mterestmg that a simple modlfisatlon to CGRP, 
the removal of 7 N-termmal ammo acids with the Cyst- 
Cys’ dlsulfide bond, converts a full agonist into a relate- 
vely potent antagonist with no apparent agonist aCtiOn 
at the receptor subtypes exammed m the current expe- 
riments Apparently, the C-termmal 30 ammo acids 
contam motifs that can bmd tightly to the liver CGRP 
receptor and somewhat less tightly to the muscle amylm 
receptor Although 8-‘71~CGRP antagomzes the vascular 
effects of CGRP (and amylm), this antagomst can also 
mhlbrt amylm action at amyhn doses that have no mea- 
surable vascular effects Therefore 8m37hCGRP should 
be a useful pharmacological tool for explormg amylm’s 
blologuz actions, and Its role m metabolic regulation and 
disorders 
3.3. conclusrons 
These results demonstrate that 8-37hCGRP IS an effec- 
tlvc mhlbltor of amyhn action m isolated skeletal mus- 
cle. The Ma are consistent with *-“‘hCGRP being a 
competltlve amyhn receptor antagonist The finding 
that this antagonist mhlblts amylm-evoked elevation of 
plasma lactate and glucose, supports the proposal that 
amylm’s metabolic effects m vwo reflect its action on 
skeletal muscle to promote glycogenolysls and I&XYS 
of lactate 
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